Julio Aguado,Alberto A. Amarilla,Atefeh Taherian Fard,Eduardo A. Albornoz,Alexander Tyshkovskiy,Marius Schwabenland,Harman K. Chaggar,Naphak Modhiran,Cecilia Gómez-Inclán,Ibrahim Javed,Alireza A. Baradar,Benjamin Liang,Lianli Peng,Malindrie Dharmaratne,Giovanni Pietrogrande,Pranesh Padmanabhan,Morgan E. Freney,Rhys Parry,Julian D. J. Sng,Ariel Isaacs,Alexander A. Khromykh,Guillermo Valenzuela Nieto,Alejandro Rojas-Fernandez,Thomas P. Davis,Marco Prinz,Bertram Bengsch,Vadim N. Gladyshev,Trent M. Woodruff,Jessica C. Mar,Daniel Watterson,Ernst J. Wolvetang

Abstract:Aging is a major risk factor for neurodegenerative diseases, and coronavirus disease 2019 (COVID-19) is linked to severe neurological manifestations. Senescent cells contribute to brain aging, but the impact of virus-induced senescence on neuropathologies is unknown. Here we show that senescent cells accumulate in aged human brain organoids and that senolytics reduce age-related inflammation and rejuvenate transcriptomic aging clocks. In postmortem brains of patients with severe COVID-19 we observed increased senescent cell accumulation compared with age-matched controls. Exposure of human brain organoids to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced cellular senescence, and transcriptomic analysis revealed a unique SARS-CoV-2 inflammatory signature. Senolytic treatment of infected brain organoids blocked viral replication and prevented senescence in distinct neuronal populations. In human-ACE2-overexpressing mice, senolytics improved COVID-19 clinical outcomes, promoted dopaminergic neuron survival and alleviated viral and proinflammatory gene expression. Collectively our results demonstrate an important role for cellular senescence in driving brain aging and SARS-CoV-2-induced neuropathology, and a therapeutic benefit of senolytic treatments.

Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology